Clinical observation of gefitinib in treatment of female patients with adenocarcinoma of lung WU
- VernacularTitle:吉非替尼治疗女性肺腺癌的临床观察
- Author:
Xiao-Ping WU
;
Ying-Zhi ZHUANG
;
Hao JIANG
;
You-Hua WU
;
Wen-Xiang DAI
;
Xiao-Hong AI
;
San-Yuan TANG
;
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Female;
Drug therapy
- From:
Cancer Research and Clinic
2006;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and adverse effects of gefitinib in the treatment of fe- male patients with advanced adenocarcinoma of lung who had failed to previous chemotherapy.Methods These patients received 250mg of gefitinib orally,once daily until disease progression or development of intol- erable toxic reaction.They were evaluated one month after treatment and every other month thereafter.Results Among the 27 evaluable patients,there were 1 CR(3.7%),11 PR(40.8%),10 SD(37.0%)and 5 PD(18.5%). The overall response rate was 44.5%(95% CI 29%～68%);and 22 patients(81.5%)gained profit(CR+PR+ SD)from the clinical therapy(95% CI 62%～94%);the mean TTP was 7.2 months.Symptomatic improvement rate was 80.0%.The main adverse effects were mild rash and diarrhea.Conclusion gefitinib has significant efficacy in the treatment of female patients with advanced tung cancer who had failed to previous chemother- apy.Adverse effects are mild.gefitinib is a suitable therapy for these patients.
